Loading clinical trials...
Loading clinical trials...
A Multi Phase II Clinical Trials Evaluating the Association of Bevacizumab With Weekly Paclitaxel and Capecitabine in First Line Treatment for Patients With Triple Negative Metastatic or Locally Advanced Cancer
Patients with triple negative metastatic breast cancer (HER2-, PR-, ER-) will receive bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have received adjuvant chemotherapy).
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
No
Centre Paul Papin
Angers, France
Clinique Tivoli
Bordeaux, France
Centre Hospitalier William Morey
Chalon-sur-Saône, France
Centre Hospitalier Intercommunal
Fréjus, France
Clinique des 4 Pavillons
Lormont, France
Hôpital Privé Clairval
Marseille, France
Centre Azuréen de Cancérologie
Mougins, France
Centre Alexis Vautrin
Nancy, France
Centre Antoine Lacassagne
Nice, France
Centre Hospitalier Régional
Orléans, France
Start Date
April 1, 2010
Primary Completion Date
March 1, 2012
Completion Date
June 1, 2014
Last Updated
March 17, 2016
64
ACTUAL participants
Paclitaxel
DRUG
Bevacizumab
DRUG
Capecitabine
DRUG
Lead Sponsor
ARCAGY/ GINECO GROUP
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions